Please see this announcement regarding a new partnership among 2 leading service providers to the world-wide biopharmaceutical industry. Quintiles, the world's largest leading CRO has selected invivodata to be its preferred provider for electronic Patient Reported Outcomes (ePRO) solutions and services.
Research Triangle Park, N.C., and Pittsburgh, PA (Vocus) January 18, 2010 -- Quintiles, the world’s leading biopharmaceutical services company, and invivodata, inc., an industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a collaboration agreement to transform the way Patient Reported Outcomes (PRO) are used in clinical research to speed drug development.
The collaborative arrangement connects invivodata’s PRO consulting, technology, and service solutions to the full suite of Quintiles’ clinical services, providing integrated processes and deliverables, It will reduce study complexity and cost as redundant services are removed throughout all phases of drug development.
“Regulators, especially the FDA, have increased the pressure on drug developers to focus on the patient’s perspective regarding drug effects, and Quintiles is working with customers to effectively manage this changing environment,” said Paula Brown Stafford, Executive Vice President, Integrated Clinical Services for Quintiles. “While the patient perspective can be obtained in various ways, real-time PRO data are common measures of drug efficacy, and ePRO is an accurate and reliable way to capture these data. Quintiles has led the CRO market place in providing electronic data capture services and ePRO is a logical extension of that leadership for our customers.
“Our collaboration with invivodata will provide handheld technology that drives high patient compliance and meets the needs of the eve
Copyright©2010 Vocus, Inc.
All rights reserved